Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec 30;22(1):1368.
doi: 10.1186/s12885-022-10480-z.

A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases

Subhadip Das  1 , Salman Faruqi  1 , Robert Nordal  1 , Yves Starreveld  2 , John Kelly  2 , Gregory Bowden  3 , John Amanie  4 , Alysa Fairchild  4 , Gerald Lim  1 , Shaun Loewen  1 , Lindsay Rowe  4 , Carla Wallace  5 , Sunita Ghosh  6 , Samir Patel  7
Affiliations
Clinical Trial

A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases

Subhadip Das et al. BMC Cancer. .

Abstract

Background: Postoperative stereotactic radiosurgery (SRS) is a standard management option for patients with resected brain metastases. Preoperative SRS may have certain advantages compared to postoperative SRS, including less uncertainty in delineation of the intact tumor compared to the postoperative resection cavity, reduced rate of leptomeningeal dissemination postoperatively, and a lower risk of radiation necrosis. The recently published ASCO-SNO-ASTRO consensus statement provides no recommendation for the preferred sequencing of radiotherapy and surgery for patients receiving both treatments for their brain metastases.

Methods: This multicenter, randomized controlled trial aims to recruit 88 patients with resectable brain metastases over an estimated three-year period. Patients with ten or fewer brain metastases with at least one resectable, fulfilling inclusion criteria will be randomized to postoperative SRS (standard arm) or preoperative SRS (investigational arm) in a 1:1 ratio. Randomization will be stratified by age (< 60 versus ≥60 years), histology (melanoma/renal cell carcinoma/sarcoma versus other), and number of metastases (one versus 2-10). In the standard arm, postoperative SRS will be delivered within 3 weeks of surgery, and all unresected metastases will receive primary SRS. In the investigational arm, enrolled patients will receive SRS of all brain metastases followed by surgery of resectable metastases within one week of SRS. In either arm, single fraction or hypofractionated SRS in three or five fractions is permitted. The primary endpoint is to assess local control at 12 months in both arms. Secondary endpoints include local control at other time points, regional/distant brain recurrence rates, leptomeningeal recurrence rates, overall survival, neurocognitive outcomes, and adverse radiation events including radiation necrosis rates in both arms.

Discussion: This trial addresses the unanswered question of the optimal sequencing of surgery and SRS in the management of patients with resectable brain metastases. No randomized data comparing preoperative and postoperative SRS for patients with brain metastases has been published to date.

Trial registration: Clinicaltrials.gov , NCT04474925; registered on July 17, 2020. Protocol version 1.0 (January 31, 2020).

Sponsor: Alberta Health Services, Edmonton, Canada (Samir Patel, MD).

Keywords: Brain metastases; Neurocognitive outcomes; Postoperative; Preoperative; Quality of life; Stereotactic radiosurgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study schema
See this image and copyright information in PMC

References

    1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48–54. doi: 10.1007/s11912-011-0203-y. - DOI - PubMed
    1. Bradley KA, Mehta MP. Management of brain metastases. Semin Oncol. 2004;31:693–701. doi: 10.1053/j.seminoncol.2004.07.012. - DOI - PubMed
    1. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29:533–540. doi: 10.1016/S0305-7372(03)00105-1. - DOI - PubMed
    1. National Comprehensive Cancer Network. Central nervous system cancers Version 01.2022. Available at http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
    1. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–1489. doi: 10.1001/jama.280.17.1485. - DOI - PubMed

Publication types

Associated data